02:00 Tue 20 Jul 2021
Alliance Pharma PLC - Half Year Trading Update
For immediate release |
|
20 July 2021 |
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Half Year Trading Update
Strong revenue growth continues
Amberen performance since acquisition in line with expectations and integration now complete
Alliance Pharma plc (AIM: APH), the international healthcare group, announces its trading update for the six months ended
The Group traded strongly with see-through revenue1 of
Our Consumer Healthcare brands continue to perform strongly, with total Consumer Healthcare revenues for the Period up 30% to
We saw an uplift in our Prescription Medicines business in the Period, with revenues increasing 12% to
Free cash flow for the Period was
"I am pleased to report that the Group continued to deliver a strong performance in the first half of 2021. Our Consumer Healthcare business continues to perform well - Kelo-cote in particular enjoyed a very strong first half. We were pleased with the first half performance from Amberen, and the integration of the brand into our US-based operations is now complete.
"We expect the Group's strong performance will continue throughout the second half and anticipate this will have a positive impact on cash generation and our ability to further deleverage by the year end."
1 See-through revenue includes sales from Nizoral™ as if they had been invoiced by Alliance. Under the terms of the transitional services agreement with Johnson & Johnson (J&J), Alliance receives the benefit of the net profit on sales of Nizoral from the date of acquisition up until the product licences in the
2 Adjusted net debt / enlarged Group EBITDA, calculated using pro forma EBITDA on a trailing 12-month basis
For further information:
Alliance Pharma plc |
+ 44 (0)1249 466966 |
|
|
|
|
|
|
Buchanan |
+ 44 (0)20 7466 5000 |
Mark Court / |
|
|
|
Numis Securities Limited |
+ 44 (0)20 7260 1000 |
Nominated Adviser: |
|
Corporate Broking: |
|
Investec Bank plc |
+ 44 (0) 20 7597 5970 |
Corporate Finance: |
|
Corporate Broking: |
|
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the
We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.
Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE